Home /
Article

CDx, NGS and regulation: five perspectives from the Pistoia Alliance

Dr Stewart McWilliams, VP of Quality and Regulatory Affairs at Almac Diagnostic Services, in conjunction with John Wise and Mike Furness from the Pistoia Alliance and Simon Patton from EMQN have produced an interesting paper on CDx, NGS and Regulation – Five Perspectives.

Companion diagnostics (CDx) are essential to the practice of precision medicine. Next-generation sequencing is an increasingly important tool in the development of CDx. However, for CDx to be deployed, many different biopharma industry sectors need to collaborate. This paper outlines some of the challenges and opportunities perceived by the biopharmaceutical industry, the Europe Molecular Quality Network, a regulatory agency, a notified body, and a CDx service provider.

View Resource
Almac Logo

Diagnostic Services

Your global partner for biomarker discovery, development & commercialisation.

Genomic Services

We offer a range of genomics platform and chemistry options, alongside expert data sciences support and a full sample management service.

Clinical Trial Assays

Comprehensive development, validation & delivery service for research and clinical use assays from our global clinical laboratories in USA, Europe and APAC.

Companion Diagnostics

A collaborative Companion Diagnostic partnership approach with a deep understanding of client needs. We offer CDx development, manufacture & commercialisation services.

Learn More

Please complete this form to view the Article

This website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies